PMID- 33353081
OWN - NLM
STAT- MEDLINE
DCOM- 20210209
LR  - 20210209
IS  - 1660-4601 (Electronic)
IS  - 1661-7827 (Print)
IS  - 1660-4601 (Linking)
VI  - 17
IP  - 24
DP  - 2020 Dec 18
TI  - Real World Use of Antidiabetic Drugs in the Years 2011-2017: A Population-Based 
      Study from Southern Italy.
LID - 10.3390/ijerph17249514 [doi]
LID - 9514
AB  - Diabetes mellitus is a metabolic disease characterized by chronic hyperglycemia. 
      The availability of new antidiabetic drugs (ADs) has led to complex treatment 
      patterns and to changes in the patterns of specific drug utilization. The aim of 
      this population-based study was to describe the pattern of antidiabetic drugs 
      (ADs) use in Southern Italy in the years 2011-2017, in relation to the updated 
      type 2 diabetes mellitus (T2DM) therapy guidelines. A retrospective cohort study 
      was conducted on T2DM patients using data from the Palermo Local Health Unit 
      (LHU) claims database and diabetologist registry. The first-line treatment was 
      investigated and incident treatments were identified and characterized at 
      baseline in terms of demographics, complications, comorbidities, concomitant 
      drugs and clinical parameters. Persistence to AD treatment was also evaluated. 
      During the study period, one-third of first ever ADs users started the treatment 
      with ADs other than metformin, in contrast to guideline recommendations. Among 
      151,711 incident AD treatments, the male to female ratio was 1.0 and the median 
      age was 66 (57-75) years. More than half (55.0%) of incident treatments 
      discontinued the therapy during the first year of treatment. In Italy, general 
      practitioners (GPs) can only prescribe first-generation ADs, while the 
      prescription of more recently marketed ADs, such as GLP-1RA, DPP4i and SGLT2i, is 
      restricted to diabetologists only, based on a therapeutic plan. The role of GPs 
      in the management of T2DM in Italy should be re-evaluated.
FAU - Ingrasciotta, Ylenia
AU  - Ingrasciotta Y
AUID- ORCID: 0000-0002-9549-6111
AD  - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, 
      University of Messina, 98125 Messina, Italy.
FAU - Bertuccio, Maria Paola
AU  - Bertuccio MP
AUID- ORCID: 0000-0002-0644-8418
AD  - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, 
      University of Messina, 98125 Messina, Italy.
FAU - Crisafulli, Salvatore
AU  - Crisafulli S
AD  - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, 
      University of Messina, 98125 Messina, Italy.
FAU - Ientile, Valentina
AU  - Ientile V
AD  - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, 
      University of Messina, 98125 Messina, Italy.
FAU - Muscianisi, Marco
AU  - Muscianisi M
AUID- ORCID: 0000-0001-8010-4042
AD  - Department of Clinical and Experimental Medicine, University of Messina, 98125 
      Messina, Italy.
FAU - L'Abbate, Luca
AU  - L'Abbate L
AD  - Department of Biomedical and Dental Sciences and Morphofunctional Imaging, 
      University of Messina, 98125 Messina, Italy.
FAU - Pastorello, Maurizio
AU  - Pastorello M
AD  - Palermo Local Health Unit, Department of Pharmacy, 90127 Palermo, Italy.
FAU - Provenzano, Vincenzo
AU  - Provenzano V
AD  - Regional Referral Centre for Insulin Pump Implantation and Diabetes, Civic 
      Hospital, Partinico, 90047 Palermo, Italy.
FAU - Scorsone, Alessandro
AU  - Scorsone A
AD  - Regional Referral Centre for Insulin Pump Implantation and Diabetes, Civic 
      Hospital, Partinico, 90047 Palermo, Italy.
FAU - Scondotto, Salvatore
AU  - Scondotto S
AD  - Department of Epidemiologic Observatory, Health Department of Sicily, 90127 
      Palermo, Italy.
FAU - Trifiro, Gianluca
AU  - Trifiro G
AUID- ORCID: 0000-0003-1147-7296
AD  - Department of Diagnostic and Public Health, University of Verona, 37134 Verona, 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201218
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Aged
MH  - *Diabetes Mellitus, Type 2/drug therapy/epidemiology
MH  - Drug Utilization
MH  - Female
MH  - Humans
MH  - *Hypoglycemic Agents/therapeutic use
MH  - Italy/epidemiology
MH  - Male
MH  - Retrospective Studies
PMC - PMC7765957
OTO - NOTNLM
OT  - Southern Italy
OT  - antidiabetic drugs
OT  - real world data
OT  - therapy guidelines
OT  - type 2 diabetes mellitus
COIS- Gianluca Trifiro declares his participation in advisory boards organized by 
      Sanofi Genzyme, Abbvie, Sanofi, GSK, Biogen, Ipsen, Novartis, Bayer; he was a 
      consultant for Otsuka; furthermore, he coordinates a pharmacoepidemiology 
      research team at the University of Messina, which receives research grants for 
      projects by PTC Therapeutics, AstraZeneca, Amgen, IBSA. The other authors declare 
      no conflict of interest.
EDAT- 2020/12/24 06:00
MHDA- 2021/02/10 06:00
PMCR- 2020/12/01
CRDT- 2020/12/23 01:02
PHST- 2020/11/19 00:00 [received]
PHST- 2020/12/15 00:00 [revised]
PHST- 2020/12/16 00:00 [accepted]
PHST- 2020/12/23 01:02 [entrez]
PHST- 2020/12/24 06:00 [pubmed]
PHST- 2021/02/10 06:00 [medline]
PHST- 2020/12/01 00:00 [pmc-release]
AID - ijerph17249514 [pii]
AID - ijerph-17-09514 [pii]
AID - 10.3390/ijerph17249514 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2020 Dec 18;17(24):9514. doi: 
      10.3390/ijerph17249514.